Company Overview

PRIME exits and American Healthcare Capital are pleased to represent a premier, non-cGMP Contract Research Organization (CRO) in California that provides services to pharmaceutical and biotechnology companies and other research-based organizations to support small-molecule drug discovery and development. In business for over 12 years, services include custom synthesis, process development, scale-up, medicinal chemistry, sourcing and procurement, and consulting in a fully equipped facility with state-of-the-art analytical and synthetic capabilities.

The Company also works within a hybrid model, collaborating with and leading programs in an India-based CRO with over 100 employees. They have leveraged that relationship to facilitate programs for certain pharmaceutical companies that will have work done overseas at a lower cost.

Financial Overview

The Company had peak sales of over $700,000 in 2021, with just over $400,000 in each of the last two years. The gross profit has been around 90% with an EBITDA margin of 40%. Revenues have declined over the past two years because the owner focuses on additional entrepreneurial business opportunities. Projected revenues for 2024 are $300,000. The Company maintains approximately $200,000 in inventory and capital equipment value.

Staff Overview

The owner is committed to ensuring a smooth transition for the new owners. He is willing to stay on for a period of up to one year, during which he will share his extensive knowledge and experience to ensure that the new owners are fully apprised of all aspects of the business. Currently, there are no other employees.

Asking Price

The price is to be determined.